15.25 USD
+0.01 (+0.07%)
15.25 USD
0 (0%)
We assign a fundamental rating of 2 out of 10 to AERI. AERI was compared to 191 industry peers in the Pharmaceuticals industry. AERI may be in some trouble as it scores bad on both profitability and health. AERI is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
- AERI had negative earnings in the past year.
- AERI had a positive operating cash flow in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.73% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -12.49% | ||
| PM (TTM) | -17.09% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- AERI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- AERI has more shares outstanding than it did 1 year ago.
- The debt/assets ratio for AERI is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -2.71, we must say that AERI is in the distress zone and has some risk of bankruptcy.
- The Debt to FCF ratio of AERI is 118.54, which is on the high side as it means it would take AERI, 118.54 years of fcf income to pay off all of its debts.
- AERI has a Debt/Equity ratio of -1.91. This is a healthy value indicating a solid balance between debt and equity.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | -1.91 | ||
| Debt/FCF | 118.54 | ||
| Altman-Z | -2.71 |
ROIC/WACCN/A
WACC8.3%
2.3 Liquidity
- A Current Ratio of 2.27 indicates that AERI has no problem at all paying its short term obligations.
- A Quick Ratio of 1.92 indicates that AERI should not have too much problems paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.92 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 94.48% over the past year.
- The Revenue has grown by 105.42% in the past year. This is a very strong growth!
- AERI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 100.24% yearly.
EPS 1Y (TTM)94.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)105.42%
Revenue growth 3Y100.24%
Revenue growth 5YN/A
Sales Q2Q%23.25%
3.2 Future
- The Earnings Per Share is expected to grow by 12.85% on average over the next years. This is quite good.
- AERI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.90% yearly.
EPS Next Y-85.62%
EPS Next 2Y-0.49%
EPS Next 3Y24.72%
EPS Next 5Y12.85%
Revenue Next Year23.8%
Revenue Next 2Y27.33%
Revenue Next 3Y26.9%
Revenue Next 5Y21.9%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- AERI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year AERI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 285.78 | ||
| EV/EBITDA | -38.22 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as AERI's earnings are expected to grow with 24.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.49%
EPS Next 3Y24.72%
5. Dividend
5.1 Amount
- No dividends for AERI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
15.25
+0.01 (+0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-03 2022-11-03/amc
Earnings (Next)02-22 2023-02-22
Inst Owners4.85%
Inst Owner Change0%
Ins Owners2.91%
Ins Owner Change0%
Market Cap753.62M
Revenue(TTM)213.94M
Net Income(TTM)-36.55M
Analysts71.43
Price Target15.63 (2.49%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.81%
Min EPS beat(2)39.47%
Max EPS beat(2)44.16%
EPS beat(4)4
Avg EPS beat(4)85.81%
Min EPS beat(4)0.99%
Max EPS beat(4)258.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.22%
Min Revenue beat(2)-0.18%
Max Revenue beat(2)0.62%
Revenue beat(4)2
Avg Revenue beat(4)63.94%
Min Revenue beat(4)-2.07%
Max Revenue beat(4)257.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.52 | ||
| P/FCF | 285.78 | ||
| P/OCF | 105.15 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | -38.22 |
EPS(TTM)-0.16
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)0.05
FCFY0.35%
OCF(TTM)0.15
OCFY0.95%
SpS4.33
BVpS-3.32
TBVpS-3.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.73% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -12.49% | ||
| PM (TTM) | -17.09% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | -1.91 | ||
| Debt/FCF | 118.54 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 70.48% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.92 | ||
| Altman-Z | -2.71 |
F-Score5
WACC8.3%
ROIC/WACCN/A
Cap/Depr(3y)97.96%
Cap/Depr(5y)541.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y-85.62%
EPS Next 2Y-0.49%
EPS Next 3Y24.72%
EPS Next 5Y12.85%
Revenue 1Y (TTM)105.42%
Revenue growth 3Y100.24%
Revenue growth 5YN/A
Sales Q2Q%23.25%
Revenue Next Year23.8%
Revenue Next 2Y27.33%
Revenue Next 3Y26.9%
Revenue Next 5Y21.9%
EBIT growth 1Y80.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.26%
EBIT Next 3Y27.69%
EBIT Next 5Y14.97%
FCF growth 1Y102.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y106.28%
OCF growth 3YN/A
OCF growth 5YN/A
AERIE PHARMACEUTICALS INC / AERI FAQ
What is the fundamental rating for AERI stock?
ChartMill assigns a fundamental rating of 3 / 10 to AERI.
What is the valuation status of AERIE PHARMACEUTICALS INC (AERI) stock?
ChartMill assigns a valuation rating of 0 / 10 to AERIE PHARMACEUTICALS INC (AERI). This can be considered as Overvalued.
Can you provide the profitability details for AERIE PHARMACEUTICALS INC?
AERIE PHARMACEUTICALS INC (AERI) has a profitability rating of 4 / 10.
What is the financial health of AERIE PHARMACEUTICALS INC (AERI) stock?
The financial health rating of AERIE PHARMACEUTICALS INC (AERI) is 2 / 10.